Bank of New York Mellon’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-300,507
| Closed | -$5.67M | – | 4307 |
|
|
2019
Q3 | $5.67M | Buy |
300,507
+12,047
| +4% | +$138K | ﹤0.01% | 2220 |
|
|
2019
Q2 | $3.4M | Buy |
288,460
+23,286
| +9% | +$282K | ﹤0.01% | 2520 |
|
|
2019
Q1 | $3.62M | Sell |
265,174
-64
| -0% | -$829 | ﹤0.01% | 2488 |
|
|
2018
Q4 | $2.72M | Sell |
265,238
-1,351
| -0.5% | -$17.3K | ﹤0.01% | 2593 |
|
|
2018
Q3 | $4.44M | Sell |
266,589
-6,271
| -2% | -$113K | ﹤0.01% | 2463 |
|
|
2018
Q2 | $4.31M | Sell |
272,860
-37,055
| -12% | -$563K | ﹤0.01% | 2473 |
|
|
2018
Q1 | $3.94M | Sell |
309,915
-10,114
| -3% | -$146K | ﹤0.01% | 2472 |
|
|
2017
Q4 | $3.66M | Buy |
320,029
+4,873
| +2% | +$54.4K | ﹤0.01% | 2501 |
|
|
2017
Q3 | $3.86M | Buy |
315,156
+82,869
| +36% | +$864K | ﹤0.01% | 2465 |
|
|
2017
Q2 | $2.66M | Buy |
232,287
+21,886
| +10% | +$405K | ﹤0.01% | 2675 |
|
|
2017
Q1 | $4.38M | Buy |
210,401
+9,218
| +5% | +$204K | ﹤0.01% | 2394 |
|
|
2016
Q4 | $4.18M | Sell |
201,183
-10,218
| -5% | -$266K | ﹤0.01% | 2421 |
|
|
2016
Q3 | $6.93M | Buy |
211,401
+13,633
| +7% | +$415K | ﹤0.01% | 2073 |
|
|
2016
Q2 | $4.94M | Buy |
197,768
+91,328
| +86% | +$2.47M | ﹤0.01% | 2216 |
|
|
2016
Q1 | $2.61M | Sell |
106,440
-16,611
| -13% | -$385K | ﹤0.01% | 2516 |
|
|
2015
Q4 | $4.07M | Buy |
123,051
+2,900
| +2% | +$98.1K | ﹤0.01% | 2338 |
|
|
2015
Q3 | $3.94M | Sell |
120,151
-2,704
| -2% | -$115K | ﹤0.01% | 2364 |
|
|
2015
Q2 | $6.51M | Buy |
122,855
+58,349
| +90% | +$2.12M | ﹤0.01% | 2197 |
|
|
2015
Q1 | $1.86M | Buy |
64,506
+16,240
| +34% | +$446K | ﹤0.01% | 2925 |
|
|
2014
Q4 | $1.4M | Buy |
48,266
+7,794
| +19% | +$140K | ﹤0.01% | 3093 |
|
|
2014
Q3 | $512K | Buy |
40,472
+1,988
| +5% | +$30K | ﹤0.01% | 3614 |
|
|
2014
Q2 | $773K | Buy |
+38,484
| New | +$542K | ﹤0.01% | 3446 |
|
Bank of New York Mellon's ALDR Position: Q4 2019 in Review
Bank of New York Mellon sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 300,507 shares — an estimated $5.67M sold.
Bank of New York Mellon first reported a position in ALDR in Q2 2014 and held it in 22 quarters. The position peaked at $6.93M in Q3 2016. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Bank of New York Mellon reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Bank of New York Mellon sold 300,507 Alder Biopharmaceuticals shares in Q4 2019, an estimated $5.67M.
- Bank of New York Mellon first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 22 quarters.
- Bank of New York Mellon's Alder Biopharmaceuticals position peaked at $6.93M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Bank of New York Mellon's 13F filing for Q4 2019, filed 14 Feb 2020.